Reports

Ideas That Generate Results

1. Analyst View

2. Research Methodology

3. Antibody Drug Conjugate (ADC) - An Introduction

4. ADC Market Outlook to 2020
     4.1 ADCETRIS
            4.1.1 Market Potential
            4.1.2 Market Size and Forecasts to 2020
     4.2 Kadcyla
            4.2.1 Market Potential
            4.2.2 Market Size and Forecasts to 2020

5. ADC Pipeline Analysis
     5.1 By Phase
     5.2 By Indication
     5.3 By Drug

6. Drivers and Challenges
     6.1 Drivers
            6.1.1 Advances in Linking Technologies Re-Instills Hope in ADC
            6.1.2 Efforts towards Patent Protection to Drive ADC Market
     6.2 Challenges
            6.2.1 Production Hurdles and Cost
            6.2.2 Inadequacy of Experienced Manufacturers
            6.2.3 Regulatory Challenges

7. Current Status of Potential ADCs in Pipeline
     7.1 Glembatumumab Vedotin Therapeutics /CDX-011 - Celldex
     7.2 Coltuximab Ravtansine/SAR3419 - Immunogen Inc.
     7.3 Indatuximab Ravtansine/BT-062 - Biotest
     7.4 Anti-PSMA ADC Therapeutic - Progenics Pharmaceuticals
     7.5 Polatuzumab Vedotin/RG7596 - Roche Genentech
     7.6 Pinatuzumab Vedotin/RG7593 - Roche Genentech
     7.7 Lifastuzumab Vedotin/RG7599 - Roche Genentech
     7.8 Anti-guanylyl Cyclase C/Anti-GCC ADC - Takeda Millennium
     7.9 Inotuzumab Ozogamicin (CMC-544) - Pfizer

8. Trends and Developments
     8.1 ADC at the Forefront to Treat Hematological Malignancies
     8.2 ADCs  Providing Advantages  to Breast Cancer Patients

9. Strategic Collaborations in the ADC Industry

10. Competitive Assessment
     10.1 Seattle Genetics
     10.2 Roche
     10.3 Immunogen, Inc.
     10.4 Bayer Healthcare
     10.5 Novartis
     10.6 Immunomedics
     10.7 Agensys, Inc